Literature DB >> 26753558

Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.

Dyfrig Hughes1, Joanna Charles2, Dalia Dawoud3, Rhiannon Tudor Edwards2, Emily Holmes2, Carys Jones2, Paul Parham4, Catrin Plumpton2, Colin Ridyard2, Huw Lloyd-Williams2, Eifiona Wood2, Seow Tien Yeo2.   

Abstract

Trial-based economic evaluations are an important aspect of health technology assessment. The availability of patient-level data coupled with unbiased estimates of clinical outcomes means that randomised controlled trials are effective vehicles for the generation of economic data. However there are methodological challenges to trial-based evaluations, including the collection of reliable data on resource use and cost, choice of health outcome measure, calculating minimally important differences, dealing with missing data, extrapolating outcomes and costs over time and the analysis of multinational trials. This review focuses on the state of the art of selective elements regarding the design, conduct, analysis and reporting of trial-based economic evaluations. The limitations of existing approaches are detailed and novel methods introduced. The review is internationally relevant but with a focus towards practice in the UK.

Entities:  

Mesh:

Year:  2016        PMID: 26753558     DOI: 10.1007/s40273-015-0371-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  62 in total

1.  The development of a QALY measure for epilepsy: NEWQOL-6D.

Authors:  Brendan Mulhern; Donna Rowen; Ann Jacoby; Tony Marson; Dee Snape; Dyfrig Hughes; Nick Latimer; Gus A Baker; John E Brazier
Journal:  Epilepsy Behav       Date:  2012-04-12       Impact factor: 2.937

Review 2.  Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals.

Authors:  Angela M Wood; Ian R White; Simon G Thompson
Journal:  Clin Trials       Date:  2004       Impact factor: 2.486

3.  Incorporating pharmacoeconomic and health outcomes into randomized clinical trials.

Authors:  Dennis A Revicki; Clark Paramore; Anne M Rentz
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2005-12       Impact factor: 2.217

4.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

Authors:  Michael Drummond; Marco Barbieri; John Cook; Henry A Glick; Joanna Lis; Farzana Malik; Shelby D Reed; Frans Rutten; Mark Sculpher; Johan Severens
Journal:  Value Health       Date:  2009-01-12       Impact factor: 5.725

Review 5.  Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.

Authors:  Scott D Ramsey; Richard J Willke; Henry Glick; Shelby D Reed; Federico Augustovski; Bengt Jonsson; Andrew Briggs; Sean D Sullivan
Journal:  Value Health       Date:  2015-03       Impact factor: 5.725

Review 6.  Inclusion of compliance and persistence in economic models: past, present and future.

Authors:  Ananth Kadambi; Robert J Leipold; Anuraag R Kansal; Sonja Sorensen; Denis Getsios
Journal:  Appl Health Econ Health Policy       Date:  2012-11-01       Impact factor: 2.561

7.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 8.  Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

Authors:  Dyfrig Hughes; Warren Cowell; Tamas Koncz; Joyce Cramer
Journal:  Value Health       Date:  2007 Nov-Dec       Impact factor: 5.725

9.  Development of a database of instruments for resource-use measurement: purpose, feasibility, and design.

Authors:  Colin H Ridyard; Dyfrig A Hughes
Journal:  Value Health       Date:  2012-05-31       Impact factor: 5.725

10.  A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments.

Authors:  Krista Fischer; Els Goetghebeur; Bernard Vrijens; Ian R White
Journal:  Biostatistics       Date:  2010-08-30       Impact factor: 5.899

View more
  16 in total

1.  Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them?

Authors:  Melina Dritsaki; Alastair Gray; Stavros Petrou; Susan Dutton; Sarah E Lamb; Joanna C Thorn
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

2.  Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT.

Authors:  Sally Hopewell; David J Keene; Peter Heine; Ioana R Marian; Melina Dritsaki; Lucy Cureton; Susan J Dutton; Helen Dakin; Andrew Carr; Willie Hamilton; Zara Hansen; Anju Jaggi; Chris Littlewood; Karen Barker; Alastair Gray; Sarah E Lamb
Journal:  Health Technol Assess       Date:  2021-08       Impact factor: 4.106

Review 3.  Modelling the cost-effectiveness of total knee arthroplasty: A systematic review.

Authors:  Achi Kamaraj; Kendrick To; Kt Matthew Seah; Wasim S Khan
Journal:  J Orthop       Date:  2020-10-08

Review 4.  Cost-effectiveness of surgical interventions for the management of osteoarthritis: a systematic review of the literature.

Authors:  Hanin Kamaruzaman; Philip Kinghorn; Raymond Oppong
Journal:  BMC Musculoskelet Disord       Date:  2017-05-10       Impact factor: 2.362

5.  Measurement tools of resource use and quality of life in clinical trials for dementia or cognitive impairment interventions: protocol for a scoping review.

Authors:  Fan Yang; Piers Dawes; Iracema Leroi; Brenda Gannon
Journal:  Syst Rev       Date:  2017-01-26

6.  Methods for estimating complier average causal effects for cost-effectiveness analysis.

Authors:  K DiazOrdaz; A J Franchini; R Grieve
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2017-05-24       Impact factor: 2.483

Review 7.  Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.

Authors:  Andrea Gabrio; Alexina J Mason; Gianluca Baio
Journal:  Pharmacoecon Open       Date:  2017-06

8.  Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.

Authors:  Shabbir M H Alibhai; Paul Ritvo; Daniel Santa Mina; Catherine Sabiston; Murray Krahn; George Tomlinson; Andrew Matthew; Himu Lukka; Padraig Warde; Sara Durbano; Meagan O'Neill; S Nicole Culos-Reed
Journal:  BMC Cancer       Date:  2018-10-23       Impact factor: 4.430

9.  A Bayesian framework for health economic evaluation in studies with missing data.

Authors:  Alexina J Mason; Manuel Gomes; Richard Grieve; James R Carpenter
Journal:  Health Econ       Date:  2018-07-03       Impact factor: 3.046

10.  An economic analysis of patient controlled remifentanil and epidural analgesia as pain relief in labour (RAVEL trial); a randomised controlled trial.

Authors:  Liv Freeman; Johanna Middeldorp; Eline van den Akker; Martijn Oudijk; Caroline Bax; Marloes van Huizen; Celine Radder; Bianca Fong; Kitty Bloemenkamp; Albert Dahan; Michel Struys; Ben Willem Mol; Jan van Lith; Elske van den Akker-van Marle
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.